N,N,3-trimethyl-5-(trifluoromethyl)aniline | 1360804-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N,3-trimethyl-5-(trifluoromethyl)aniline
• CAS: 1360804-17-6
• 化学式: C₁₀H₁₂F₃N
• 分子量: 203.207
• InChiKey: PQRHGRIJFZBZEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N,N-二甲基-间甲基苯胺 在 potassium fluoride 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 4,4'-ditert-butyl-2,2'-bipyridine 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 N,N,3-trimethyl-5-(trifluoromethyl)aniline
  参考文献：
  名称：

  使用芳基硼酸酯和 [(phen)CuRF] 对芳烃和芳溴化物进行全氟烷基化的一般策略

  摘要：

  描述了一种从芳烃和芳基溴化物合成芳基全氟烷烃的通用方法。取代的芳烃或芳基溴化物在原位转化为芳基硼酸酯，该芳基硼酸酯易于在空气中与 [(phen)CuR F ]进行全氟烷基化。广泛的芳基溴底物首次以良好的产率全氟烷基化。[(phen)CuCF 3 ] 现在可商购并已以 20 g 的规模制备。

  DOI：

  10.1002/anie.201106668

文献信息

• SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS
  申请人：INCYTE CORPORATION

  公开号：US20130274257A1

  公开（公告）日：2013-10-17

  The present invention provides substituted tricyclic heteroaryl compounds, including, for example, pyridoindoles, pyrimidinoindoles and triazinoindoles that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases such as immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了取代的三环杂芳基化合物，包括例如吡啶并吲哚、嘧啶并吲哚和三唑并吲哚，这些化合物调节Janus激酶的活性，并可用于治疗与Janus激酶活性相关的疾病，如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。
• AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
  申请人：ORIBASE PHARMA

  公开号：US20150353540A1

  公开（公告）日：2015-12-10

  The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

  本发明涉及以下式(I)化合物及/或其药学上可接受的加合物、溶剂化物、对映体、非对映异构体以及它们的混合物。因此，本发明的主题还包括制备式(I)化合物、它们的用途，特别是在抑制蛋白激酶方面的应用，这些蛋白激酶例如与许多疾病（如癌症或免疫系统紊乱）有关。
• AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS
  申请人：ORIBASE PHARMA

  公开号：US20150353539A1

  公开（公告）日：2015-12-10

  The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

  本发明涉及以下式(I)的化合物和/或其药学上可接受的加合盐、溶剂化物、对映体、非对映异构体以及它们的混合物。因此，本发明的主题还包括制备式(I)化合物，它们的用途，特别是在抑制蛋白激酶方面的用途，这些蛋白激酶例如与许多疾病有关，如癌症或免疫系统紊乱。
• PROTEIN KINASE INHIBITORS
  申请人：ORIBASE PHARMA

  公开号：US20160009709A1

  公开（公告）日：2016-01-14

  The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

  本发明涉及以下式(I)的化合物和/或其药学上可接受的加成盐、溶剂化物、对映体、非对映异构体以及其混合物。因此，本发明的主题还包括制备式(I)的化合物，它们的用途，特别是在抑制蛋白激酶方面的应用，例如在许多疾病，如癌症或免疫系统紊乱中涉及的蛋白激酶。
• Glycopeptide Antibiotic Monomer Derivatives
  申请人：Arimoto Hirokazu

  公开号：US20080097078A1

  公开（公告）日：2008-04-24

  Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—R A [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and R A represents, e.g., the formula —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 (wherein X 1 , X 2 , and X 3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR 1 —, —O—, etc.; Y represents —NR 2 CO— or —CONR 2 — (wherein R 2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.